Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

All NewsMarch 23, 2026

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent